LYPHF Stock Latest News
Company AnnouncementsLuye Pharma’s Ruoxinlin Approved for Generalized Anxiety Disorder in China1d ago
Company AnnouncementsLuye Pharma Receives U.S. Trial Clearance for LY030213d ago
Company AnnouncementsLuye Pharma’s Ruoxinlin Renewed in China’s 2026 Reimbursement Drug List5d ago
Company AnnouncementsLuye Pharma Delivers Higher H1 Profit Despite Revenue Decline2M ago
Company AnnouncementsLuye Pharma Advances HPV mRNA Vaccine LY01620 to Phase II in China3M ago
Company AnnouncementsLuye Pharma Sets Board Meeting to Approve Interim Results and Consider Dividend3M agoCompany AnnouncementsLuye Pharma Advances CNS Portfolio With Successful U.S. Bridging Trial for LY030153M ago
Company AnnouncementsLuye Pharma Wins Shareholder Backing for All AGM Resolutions and Capital Mandates4M ago
Company AnnouncementsLuye Pharma’s Novel CNS Drug LY03015 Delivers Strong Phase 2 Data in Tardive Dyskinesia5M ago
Company AnnouncementsLuye Pharma Halves 2028 Convertible Bond Float With US$89.74 Million Buyback5M ago
Company AnnouncementsLuye Pharma Raises US$180 Million via Premium-Priced 2031 Convertible Bonds5M ago
Company AnnouncementsLuye Pharma Wins Vienna MTF Listing Approval for New Bond Issue5M ago
Company AnnouncementsLuye Pharma to Swap 2028 Convertible Debt with New 2031 Issue5M agoCompany AnnouncementsLuye Pharma sets 2026 AGM to renew board, auditor and share issuance mandate5M ago
Company AnnouncementsLuye Pharma Starts U.S. PK Bridging Trial for Novel CNS Drug LY030157M ago
Company AnnouncementsLuye Pharma Advances Alzheimer’s Psychosis Drug LY03017 Into China Phase II Trial7M ago
Company AnnouncementsLuye Pharma Starts Phase II Trial in China for Next-Generation Schizophrenia Drug LY030207M ago
Company AnnouncementsLuye Pharma Delivers Double-Digit Profit Growth in 2025 but Skips Dividend7M ago
Company AnnouncementsLuye Pharma Sets March 2026 Board Meeting to Approve 2025 Results8M agoCompany AnnouncementsLuye Pharma Completes RMB1.09 Billion Transfer of 25% Stake in Nanjing Luye to NJ Xinshi9M ago

